Kairos Pharma (KAPA) plans to collaborate with PreCheck Health Services, a clinical laboratory specializing in genetic sequencing, to develop companion biomarkers for Kairos' ENV105 therapy targeting prostate and lung cancers.
The partnership aims to advance the "precision" of patient screening and therapy monitoring in phase 1 and 2 clinical trials of ENV105, advancing treatment by identifying patients who will benefit most, Kairos Pharma said Tuesday in a statement.
Kairos Pharma shares rose 16% in recent after-hours trading.
Price: 2.34, Change: +0.33, Percent Change: +16.42
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。